PAT-ChIP coupled with laser microdissection allows the study of chromatin in selected cell populations from paraffin-embedded patient samples

Epigenetics & Chromatin

Mirco Fanelli⁵  Saverio Minucci³  Pier Giuseppe Pelicci²  Silvano Bosari⁴  Fulvia Fusar²  Elena Belloni²  Alice Faversani¹  Marco Ballarini²  Stefano Amatori² 

[1] Division of Pathology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Via Francesco Sforza, 33, Milan 20122, Italy;Department of Experimental Oncology, European Institute of Oncology, Via Adamello, 16, Milan 20139, Italy;Department of Biosciences, University of Milan, Via Giovanni Celoria, 26, Milan 20133, Italy;Department of Pathophysiology and Transplantation, University of Milan, Via Francesco Sforza, 35, Milan 20122, Italy;Department of Biomolecular Sciences, University of Urbino ‘Carlo Bo’, Molecular Pathology Lab. ‘PaoLa’, Via Arco d'Augusto, 2, Fano 61032, Italy

关键词: FFPE samples;    Pathology samples;    Laser microdissection;    PAT-ChIP;    Chromatin immunoprecipitation;   

Others  :  1120573
DOI  :  10.1186/1756-8935-7-18

 received in 2014-03-13, accepted in 2014-07-18,  发布年份 2014

【 摘 要 】

Background

The recent introduction of pathology tissue-chromatin immunoprecipitation (PAT-ChIP), a technique allowing chromatin immunoprecipitation from formalin-fixed and paraffin-embedded (FFPE) tissues, has expanded the application potential of epigenetic studies in tissue samples. However, FFPE tissue section analysis is strongly limited by tissue heterogeneity, which hinders linking the observed epigenetic events to the corresponding cellular population. Thus, ideally, to take full advantage of PAT-ChIP approaches, procedures able to increase the purity and homogeneity of cell populations from FFPE tissues are required.

Results

In this study, we tested the use of both core needle biopsies (CNBs) and laser microdissection (LMD), evaluating the compatibility of these methods with the PAT-ChIP procedure. Modifications of the original protocols were introduced in order to increase reproducibility and reduce experimental time. We first demonstrated that chromatin can be prepared and effectively immunoprecipitated starting from 0.6-mm-diameter CNBs. Subsequently, in order to assess the applicability of PAT-ChIP to LMD samples, we tested the effects of hematoxylin or eosin staining on chromatin extraction and immunoprecipitation, as well as the reproducibility of our technique when using particularly low quantities of starting material. Finally, we carried out the PAT-ChIP using chromatin extracted from either normal tissue or neoplastic lesions, the latter obtained by LMD from FFPE lung sections derived from mutant K-ras^v12 transgenic mice or from human adeno- or squamous lung carcinoma samples. Well characterized histone post-translational modifications (HPTMs), such as H3K4me3, H3K27me3, H3K27Ac, and H3K9me3, were specifically immunoselected, as well as the CTCF transcription factor and RNA polymerase II (Pol II).

Conclusions

Epigenetic profiling can be performed on enriched cell populations obtained from FFPE tissue sections. The improved PAT-ChIP protocol will be used for the discovery and/or validation of novel epigenetic biomarkers in FFPE human samples.

【 授权许可】

   
2014 Amatori et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Meissner A, Bernstein BE: Sequencing the epigenome. In Epigenomics. Part I. Edited by Ferguson-Smith AC, Greally JM, Martienssen RA. Dordrecht: Springer; 2009:19-35.
• [2]Timp W, Feinberg AP: Cancer as a dysregulated epigenome allowing cellular growth advantage at the expense of the host. Nat Rev Cancer 2013, 13:497-510.
• [3]Esteller M: Epigenetics in cancer. N Engl J Med 2008, 358:1148-1159.
• [4]Halliwell B: Oxidative stress in cell culture: an under-appreciated problem? FEBS Lett 2003, 540:3-6.
• [5]Baker DEC, Harrison NJ, Maltby E, Smith K, Moore HD, Shaw PJ, Heath PR, Holden H, Andrews PW: Adaptation to culture of human embryonic stem cells and oncogenesis in vivo. Nat Biotechnol 2007, 25:207-215.
• [6]Collas P, Dahl JA: Chop it, ChIP it, checkit: the current status of chromatin immunoprecipitation. Front Biosci 2008, 13:929-943.
• [7]O'Neill LP, VerMilyea MD, Turner BM: Epigenetic characterization of the early embryo with a chromatin immunoprecipitation protocol applicable to small cell populations. Nat Genet 2006, 38:835-841.
• [8]Pan G, Tian S, Nie J, Yang C, Ruotti V, We H, Jonsdottir GA, Stewart R, Thomson GA: Whole-genome analysis of histone H3 lysine 4 and lysine 27 methylation in human embryonic stem cells. Cell Stem Cell 2007, 1:299-312.
• [9]Zhao XD, Han X, Chew JL, Liu J, Chiu KP, Choo A, Orlov YL, Sung WK, Shahab A, Kuznetsov VA, Bourque G, Oh S, Ruan Y, Ng HH, Wei CL: Whole-genome mapping of histone H3 Lys4 and 27 trimethylations reveals distinct genomic compartments in human embryonic stem cells. Cell Stem Cell 2007, 1:286-298.
• [10]O'Neill LP, Turner BM: Histone H4 acetylation distinguishes coding regions of the human genome from heterochromatin in a differentiation-dependent but transcription-independent manner. EMBO J 1995, 14:3946-3957.
• [11]Collas P: The current state of chromatin immunoprecipitation. Mol Biotechnol 2010, 45:87-100.
• [12]Park PJ: ChIP–seq: advantages and challenges of a maturing technology. Nat Rev Genet 2009, 10:669-680.
• [13]Einav Nili GY, Saito Y, Egger G, Jones PA: Cancer epigenetics: modifications, screening, and therapy. Annu Rev Med 2008, 59:267-280.
• [14]Laird PW: The power and the promise of DNA methylation markers. Nat Rev Cancer 2003, 3:253-266.
• [15]Fanelli M, Amatori S, Barozzi I, Soncini M, Dal Zuffo R, Bucci G, Capra M, Quarto M, Dellino GI, Mercurio C, Alcalay M, Viale G, Pelicci PG, Minucci S: Pathology tissue-chromatin immunoprecipitation, coupled with high-throughput sequencing, allows the epigenetic profiling of patient samples. Proc Natl Acad Sci USA 2010, 107:21535-21540.
• [16]Fanelli M, Amatori S, Barozzi I, Minucci S: Chromatin immunoprecipitation and high-throughput sequencing from paraffin-embedded pathology tissue. Nat Protoc 2011, 6:1905-1919.
• [17]Bubendorf L, Nocito A, Moch H, Sauter G: Tissue microarray (TMA) technology: miniaturized pathology archives for high-throughput in situ studies. J Pathol 2001, 195:72-79.
• [18]Simon R, Mirlacher M, Sauter G: Tissue microarrays. In Molecular Diagnosis of Cancer. 2nd edition. Edited by Roulston JE, Barlett JMS. New York: Humana Press; 2004:377-389.
• [19]Espina V, Wulfkuhle JD, Calvert VS, Van Meter A, Zhou W, Coukos G, Geho DH III, Petricoin EF, Liotta LA: Laser-capture microdissection. Nat Protoc 2006, 1:586-603.
• [20]Bonner RF, Emmert-Buck M, Cole K, Pohida T, Chuaqui R, Goldstein S, Liotta LA: Laser capture microdissection: molecular analysis of tissue. Science 1997, 278:1481-1483.
• [21]Guerra C, Mijimolle N, Dhawahir A, Dubus P, Barradas M, Serrano M, Campuzano V, Barbacid M: Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context. Cancer Cell 2003, 4:111-120.
• [22]Minucci S, Monestiroli S, Giavara S, Ronzoni S, Marchesi F, Insinga A, Diverio D, Gasparini P, Capillo M, Colombo E, Matteucci C, Contegno F, Lo-Coco F, Scanzini E, Gobbi A, Pelicci PG: PML-RAR induces promyelocytic leukemias with high efficiency following retroviral gene transfer into purified murine hematopoietic progenitors. Blood 2002, 100:2989-2995.
• [23]Vaira V, Faversani A, Dohi T, Montorsi M, Augello C, Gatti S, Coggi G, Altieri DC, Bosari S: miR-296 regulation of a cell polarity-cell plasticity module controls tumor progression. Oncogene 2012, 31(1):27-38.
• [24]Amatori S, Bagaloni I, Macedi E, Formica M, Giorgi L, Fusi V, Fanelli M: Malten, a new synthetic molecule showing in vitro antiproliferative activity against tumor cells and induction of complex DNA structural alterations. Br J Cancer 2010, 2:239-248.